The beat-and-raise quarter with broad-based growth across all species and accelerating innovation momentum is a strong positive catalyst. Watch for Q2 guidance ($1.30-$1.325B revenue, $0.25-$0.28 adjusted EPS) as a near-term check on execution. The improved net leverage target (3.0x-3.2x) and Elanco Ascend savings trajectory support further margin expansion. Monitor Befrena commercialization in Q2 and the AHV International integration.
ELAN drugs
ELAN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $26.14entry
- T+1 · 6mo ago −8.38%α −8.05% · $23.95
- T+5 · 6mo ago −18.01%α −19.14% · $21.43
- T+20 · 6mo ago −6.00%α −8.78% · $24.57
- T+60 · 4mo ago +1.23%α +0.16% · $26.46
Price Chart
How similar events traded
Executive Summary
Elanco reported Q1 2026 adjusted EPS of $0.40, beating the $0.34 consensus by 17.6%, on revenue of $1.371B (+15% YoY, +10% organic constant currency), exceeding the $1.28B consensus. The company raised full-year 2026 guidance across all key metrics: revenue to $5.01-$5.085B, adjusted EBITDA to $975M-$1.005B, and adjusted EPS to $1.03-$1.09, driven by accelerating innovation portfolio momentum (Zenrelia blockbuster, Credelio Quattro share gains) and Elanco Ascend productivity savings.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $1.371B, +15% YoY reported, +10% organic constant currency, vs consensus $1.28B
- Adjusted EPS $0.40 vs consensus $0.34 (+17.6% beat) and vs $0.37 in Q1 2025 (+8% YoY)
- Adjusted EBITDA $334M, +21% YoY; margin expanded to 24.5% from 23.1%
- Raised FY2026 guidance: revenue to $5.01-$5.085B (from $4.95-$5.02B), adjusted EBITDA to $975M-$1.005B, adjusted EPS to $1.03-$1.09
- Innovation revenue target raised to $1.2B; Zenrelia reached trailing 4-quarter blockbuster status
- Net leverage ratio improved to 3.5x from 3.6x at year-end 2025; year-end target improved to 3.0x-3.2x
- Closed acquisition of AHV International on April 30, 2026
Financial Impact
Q1 revenue beat consensus by ~$91M (7.1%); adjusted EPS beat by $0.06 (17.6%)
Risk Factors
- GAAP net income declined 15% YoY to $57M due to higher interest expense and restructuring charges
- Adjusted gross margin contracted 40bps to 57.0% on product mix and inflation
- Operating cash flow was only $13M in Q1, though improved from -$4M a year ago
- Elevated net debt of $3.335B and leverage of 3.5x still above long-term target of 2.0x-2.5x
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001739104-26-000027 |
| Document: elan-20260506.htm | 0001739104-26-000027 |
| Document: 0001739104-26-000027-index-headers.html | 0001739104-26-000027 |
| Document: 0001739104-26-000027-index.html | 0001739104-26-000027 |
| Document: 0001739104-26-000027.txt | 0001739104-26-000027 |
| 8-K Data (Synthetic) | 0001739104-26-000027 |
Track record
19 reports on ELAN
4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +15.03% at T+5 after the May 19, 2026 report. 8 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $26.68 Now $26.41 −1.01% settles Feb 12
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $26.78 Now $26.41 −1.38% settles Feb 11
- Nov 6, 202610d ago 8-K Bullish 6/10 Entry $25.74 Now $26.41 +2.60% settles Feb 4
- Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $23.68 Now $26.41 +11.53% settles Feb 3
- Nov 3, 202613d ago 3 Neutral 1/10 Entry $25.31 Now $26.41 +4.35% settles Feb 2
- Oct 14, 20264w ago Institutional Cluster Bullish 4/10 Entry $23.54 Now $26.41 +12.19% settles Jan 12
- Sep 11, 20269w ago Press Release Neutral 1/10 Entry $23.17 Now $26.41 +13.98% settles Dec 7
- Aug 21, 202612w ago Insider Cluster Bullish 6/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 21, 202612w ago Insider Cluster Bullish 4/10 Entry $24.42 Now $26.41 +8.15% settles Nov 17
- Aug 18, 202612w ago Insider Cluster Bullish 4/10 Entry $24.50 to $26.50 Now $26.41 +7.80% ▲ +8.16% +9.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers